Indications

Prevention of Cardiovascular Events: In adults with established cardiovascular disease, Repatha® is indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization.

Primary Hyperlipidemia (including Heterozygous Familial Hypercholesterolemia): Repatha® is indicated as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C).

Homozygous Familial Hypercholesterolemia: Repatha® is indicated as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C.

The safety and effectiveness of Repatha® have not been established in pediatric patients with HoFH who are younger than 13 years old or in pediatric patients with primary hyperlipidemia or HeFH.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Please click here to see additional Important Safety Information on page 17.
Hyperlipidemia and Ischemic Heart Disease

Primary ICD-10 Codes

- **Disorders of lipoprotein metabolism and other lipidemias**
  - E78.00 Pure hypercholesterolemia, unspecified
  - E78.01 Familial hypercholesterolemia
  - E78.2 Mixed hyperlipidemia
  - E78.4 Other hyperlipidemia
  - E78.5 Hyperlipidemia, unspecified

Secondary ICD-10 Codes

- **Atherosclerosis and atherosclerotic heart disease**
  - I25.10 Atherosclerotic heart disease of native coronary artery without angina pectoris
  - I25.110 Atherosclerotic heart disease of native coronary artery with unstable angina pectoris
  - I25.111 Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm
  - I25.118 Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris
  - I25.119 Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris
  - I25.700 Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris
  - I25.701 Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm
  - I25.708 Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris
  - I25.709 Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris
  - I25.710 Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris
  - I25.711 Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm
  - I25.718 Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris
  - I25.719 Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris
  - I25.720 Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris
  - I25.721 Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm
  - I25.728 Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris
  - I25.729 Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris
  - I25.730 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris
  - I25.731 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm
  - I25.738 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris
  - I25.739 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris
  - I25.750 Atherosclerosis of native coronary artery of transplanted heart with unstable angina
  - I25.751 Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm

**Important Safety Information**

**Allergic Reactions:** Hypersensitivity reactions (e.g. angioedema, rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please [click here](#) to see additional Important Safety Information on page 17.
Ischemic Heart Disease (cont’d)

I25.758 Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris
I25.759 Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris
I25.760 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina
I25.761 Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm
I25.768 Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris
I25.769 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris
I25.790 Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris
I25.791 Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm
I25.798 Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris
I25.799 Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris
I25.810 Atherosclerosis of coronary artery bypass graft(s) without angina pectoris
I25.811 Atherosclerosis of native coronary artery of transplanted heart without angina pectoris
I25.812 Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris

Ischemic heart disease (other)

I20.8 Other forms of angina pectoris
I20.9 Angina pectoris, unspecified
I23.7 Postinfarction angina
I24.0 Acute coronary thrombosis not resulting in myocardial infarction
I24.8 Other forms of acute ischemic heart disease
I25.2 Old myocardial infarction
I25.3 Aneurysm of heart
I25.41 Coronary artery aneurysm
I25.42 Coronary artery dissection
I25.5 Ischemic cardiomyopathy
I25.6 Silent myocardial ischemia
I25.82 Chronic total occlusion of coronary artery
I25.83 Coronary atherosclerosis due to lipid rich plaque
I25.84 Coronary atherosclerosis due to calcified coronary lesion
I25.89 Other forms of chronic ischemic heart disease
I25.9 Chronic ischemic heart disease, unspecified

Important Safety Information

Adverse Reactions in Primary Hyperlipidemia (including HeFH): The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

Please click here to see additional Important Safety Information on page 17.
## Ischemic Heart Disease (cont’d) and Cerebrovascular Diseases

### ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I21.01</td>
<td>ST elevation (STEMI) myocardial infarction involving left main coronary artery</td>
</tr>
<tr>
<td>I21.02</td>
<td>ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery</td>
</tr>
<tr>
<td>I21.09</td>
<td>ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall</td>
</tr>
<tr>
<td>I21.11</td>
<td>ST elevation (STEMI) myocardial infarction involving right coronary artery</td>
</tr>
<tr>
<td>I21.19</td>
<td>ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall</td>
</tr>
<tr>
<td>I21.21</td>
<td>ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery</td>
</tr>
<tr>
<td>I21.29</td>
<td>ST elevation (STEMI) myocardial infarction involving other sites</td>
</tr>
<tr>
<td>I21.3</td>
<td>ST elevation (STEMI) myocardial infarction of unspecified site</td>
</tr>
<tr>
<td>I21.4</td>
<td>Non-ST elevation (NSTEMI) myocardial infarction</td>
</tr>
<tr>
<td>I22.0</td>
<td>Subsequent ST elevation (STEMI) myocardial infarction of anterior wall</td>
</tr>
<tr>
<td>I22.1</td>
<td>Subsequent ST elevation (STEMI) myocardial infarction of inferior wall</td>
</tr>
<tr>
<td>I22.2</td>
<td>Subsequent non-ST elevation (NSTEMI) myocardial infarction</td>
</tr>
<tr>
<td>I22.8</td>
<td>Subsequent ST elevation (STEMI) myocardial infarction of other sites</td>
</tr>
<tr>
<td>I22.9</td>
<td>Subsequent ST elevation (STEMI) myocardial infarction of unspecified site</td>
</tr>
</tbody>
</table>

### Presence of cardiac and vascular implants and grafts and other postprocedural states

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z95.1</td>
<td>Presence of aortocoronary bypass graft</td>
</tr>
<tr>
<td>Z95.5</td>
<td>Presence of coronary angioplasty implant and graft</td>
</tr>
<tr>
<td>Z98.61</td>
<td>Coronary angioplasty status</td>
</tr>
</tbody>
</table>

### Occlusion and stenosis of precerebral and cerebral arteries, not resulting in cerebral infarction

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I65.01</td>
<td>Occlusion and stenosis of right vertebral artery</td>
</tr>
<tr>
<td>I65.02</td>
<td>Occlusion and stenosis of left vertebral artery</td>
</tr>
<tr>
<td>I65.03</td>
<td>Occlusion and stenosis of bilateral vertebral arteries</td>
</tr>
<tr>
<td>I65.09</td>
<td>Occlusion and stenosis of unspecified vertebral artery</td>
</tr>
<tr>
<td>I65.1</td>
<td>Occlusion and stenosis of basilar artery</td>
</tr>
<tr>
<td>I65.21</td>
<td>Occlusion and stenosis of right carotid artery</td>
</tr>
<tr>
<td>I65.22</td>
<td>Occlusion and stenosis of left carotid artery</td>
</tr>
<tr>
<td>I65.23</td>
<td>Occlusion and stenosis of bilateral carotid arteries</td>
</tr>
<tr>
<td>I65.29</td>
<td>Occlusion and stenosis of unspecified carotid artery</td>
</tr>
<tr>
<td>I65.8</td>
<td>Occlusion and stenosis of other precerebral arteries</td>
</tr>
<tr>
<td>I65.9</td>
<td>Occlusion and stenosis of unspecified precerebral artery</td>
</tr>
<tr>
<td>I66.01</td>
<td>Occlusion and stenosis of right middle cerebral artery</td>
</tr>
<tr>
<td>I66.02</td>
<td>Occlusion and stenosis of left middle cerebral artery</td>
</tr>
<tr>
<td>I66.03</td>
<td>Occlusion and stenosis of bilateral middle cerebral arteries</td>
</tr>
<tr>
<td>I66.09</td>
<td>Occlusion and stenosis of unspecified middle cerebral artery</td>
</tr>
<tr>
<td>I66.11</td>
<td>Occlusion and stenosis of right anterior cerebral artery</td>
</tr>
<tr>
<td>I66.12</td>
<td>Occlusion and stenosis of left anterior cerebral artery</td>
</tr>
</tbody>
</table>

## Important Safety Information

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

Please click here to see additional Important Safety Information on page 17.
Cerebrovascular Diseases (cont’d)

I66.13 Occlusion and stenosis of bilateral anterior cerebral arteries
I66.19 Occlusion and stenosis of unspecified anterior cerebral artery
I66.21 Occlusion and stenosis of right posterior cerebral artery
I66.22 Occlusion and stenosis of left posterior cerebral artery
I66.23 Occlusion and stenosis of bilateral posterior cerebral arteries
I66.29 Occlusion and stenosis of unspecified posterior cerebral artery
I66.3 Occlusion and stenosis of cerebellar arteries
I66.8 Occlusion and stenosis of other cerebral arteries
I66.9 Occlusion and stenosis of unspecified cerebral artery

Cerebrovascular diseases (other)

I67.2 Cerebral atherosclerosis
I67.5 Moyamoya disease
I67.81 Acute cerebrovascular insufficiency
I67.82 Cerebral ischemia
I67.89 Other cerebrovascular disease
I67.9 Cerebrovascular disease, unspecified
I68.0 Cerebral amyloid angiopathy
I68.8 Other cerebrovascular disorders in diseases classified elsewhere

Cerebral infarction

I63.00 Cerebral infarction due to thrombosis of unspecified precerebral artery
I63.011 Cerebral infarction due to thrombosis of right vertebral artery
I63.012 Cerebral infarction due to thrombosis of left vertebral artery
I63.019 Cerebral infarction due to thrombosis of unspecified vertebral artery
I63.02 Cerebral infarction due to thrombosis of basilar artery
I63.031 Cerebral infarction due to thrombosis of right carotid artery
I63.032 Cerebral infarction due to thrombosis of left carotid artery
I63.039 Cerebral infarction due to thrombosis of unspecified carotid artery
I63.09 Cerebral infarction due to thrombosis of other precerebral artery
I63.20 Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries
I63.211 Cerebral infarction due to unspecified occlusion or stenosis of right vertebral arteries
I63.212 Cerebral infarction due to unspecified occlusion or stenosis of left vertebral arteries
I63.219 Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries

Important Safety Information

Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Please click here to see additional Important Safety Information on page 17.
Cerebrovascular Diseases (cont’d)

Cerebral infarction (cont’d)

I63.22 Cerebral infarction due to unspecified occlusion or stenosis of basilar arteries
I63.231 Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries
I63.232 Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries
I63.239 Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries
I63.29 Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries
I63.30 Cerebral infarction due to thrombosis of unspecified cerebral artery
I63.311 Cerebral infarction due to thrombosis of right middle cerebral artery
I63.312 Cerebral infarction due to thrombosis of left middle cerebral artery
I63.319 Cerebral infarction due to thrombosis of unspecified middle cerebral artery
I63.321 Cerebral infarction due to thrombosis of right anterior cerebral artery
I63.322 Cerebral infarction due to thrombosis of left anterior cerebral artery
I63.329 Cerebral infarction due to thrombosis of unspecified anterior cerebral artery
I63.331 Cerebral infarction due to thrombosis of right posterior cerebral artery
I63.332 Cerebral infarction due to thrombosis of left posterior cerebral artery
I63.339 Cerebral infarction due to thrombosis of unspecified posterior cerebral artery
I63.341 Cerebral infarction due to thrombosis of right cerebellar artery
I63.342 Cerebral infarction due to thrombosis of left cerebellar artery
I63.349 Cerebral infarction due to thrombosis of unspecified cerebellar artery
I63.39 Cerebral infarction due to thrombosis of other cerebral artery
I63.50 Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery
I63.511 Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery
I63.512 Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery
I63.519 Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery
I63.521 Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery
I63.522 Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery
I63.529 Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery
I63.531 Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery
I63.532 Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery
I63.539 Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery
I63.541 Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery
I63.542 Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery

Important Safety Information

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Please click here to see additional Important Safety Information on page 17.
Cerebrovascular Diseases (cont’d) and Diseases of Arteries, Arterioles, and Capillaries

I63.549 Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery
I63.59 Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery
I63.8 Other cerebral infarction
I63.9 Cerebral infarction, unspecified

Transient cerebral ischemic attack
Z86.73 Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
G45.8 Other transient cerebral ischemic attacks and related syndromes
G45.9 Transient cerebral ischemic attack, unspecified

History of transient ischemic attack (TIA) or cerebral infarction without residuals
Z86.73 Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits

Vascular syndromes of brain in cerebrovascular diseases
G46.0 Middle cerebral artery syndrome
G46.1 Anterior cerebral artery syndrome
G46.2 Posterior cerebral artery syndrome
G46.3 Brain stem stroke syndrome
G46.4 Cerebellar stroke syndrome
G46.5 Pure motor lacunar syndrome
G46.6 Pure sensory lacunar syndrome
G46.7 Other lacunar syndromes
G46.8 Other vascular syndromes of brain in cerebrovascular diseases

Atherosclerosis
I70.0 Atherosclerosis of aorta
I70.1 Atherosclerosis of renal artery
I70.201 Unspecified atherosclerosis of native arteries of extremities, right leg
I70.202 Unspecified atherosclerosis of native arteries of extremities, left leg
I70.203 Unspecified atherosclerosis of native arteries of extremities, bilateral legs
I70.208 Unspecified atherosclerosis of native arteries of extremities, other extremity
I70.209 Unspecified atherosclerosis of native arteries of extremities, unspecified extremity
I70.211 Atherosclerosis of native arteries of extremities with intermittent claudication, right leg
I70.212 Atherosclerosis of native arteries of extremities with intermittent claudication, left leg

Important Safety Information

Adverse Reactions in the Cardiovascular Outcomes Trial: Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

Please click here to see additional Important Safety Information on page 17.
Atherosclerosis (cont’d)

I70.213 Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs
I70.218 Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity
I70.219 Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity
I70.221 Atherosclerosis of native arteries of extremities with rest pain, right leg
I70.222 Atherosclerosis of native arteries of extremities with rest pain, left leg
I70.223 Atherosclerosis of native arteries of extremities with rest pain, bilateral legs
I70.228 Atherosclerosis of native arteries of extremities with rest pain, other extremity
I70.229 Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity
I70.231 Atherosclerosis of native arteries of right leg with ulceration of thigh
I70.232 Atherosclerosis of native arteries of right leg with ulceration of calf
I70.233 Atherosclerosis of native arteries of right leg with ulceration of ankle
I70.234 Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot
I70.235 Atherosclerosis of native arteries of right leg with ulceration of other part of foot
I70.238 Atherosclerosis of native arteries of right leg with ulceration of other part of lower right leg
I70.239 Atherosclerosis of native arteries of right leg with ulceration of unspecified site

I70.241 Atherosclerosis of native arteries of left leg with ulceration of thigh
I70.242 Atherosclerosis of native arteries of left leg with ulceration of calf
I70.243 Atherosclerosis of native arteries of left leg with ulceration of ankle
I70.244 Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot
I70.245 Atherosclerosis of native arteries of left leg with ulceration of other part of foot
I70.248 Atherosclerosis of native arteries of left leg with ulceration of other part of lower left leg
I70.249 Atherosclerosis of native arteries of left leg with ulceration of unspecified site
I70.25 Atherosclerosis of native arteries of other extremities with ulceration
I70.261 Atherosclerosis of native arteries of extremities with gangrene, right leg
I70.262 Atherosclerosis of native arteries of extremities with gangrene, left leg
I70.263 Atherosclerosis of native arteries of extremities with gangrene, bilateral legs
I70.268 Atherosclerosis of native arteries of extremities with gangrene, other extremity
I70.269 Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity
I70.291 Other atherosclerosis of native arteries of extremities, right leg
I70.292 Other atherosclerosis of native arteries of extremities, left leg
I70.293 Other atherosclerosis of native arteries of extremities, bilateral legs
I70.298 Other atherosclerosis of native arteries of extremities, other extremity

Important Safety Information

Adverse Reactions in Homozygous Familial Hypercholesterolemia (HoFH): The adverse reactions that occurred in at least two patients treated with Repatha® and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis.

Please click here to see additional Important Safety Information on page 17.
Diseases of Arteries, Arterioles, and Capillaries (cont’d)

I70.299 Other atherosclerosis of native arteries of extremities, unspecified extremity
I70.301 Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg
I70.302 Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg
I70.303 Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs
I70.308 Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity
I70.309 Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity
I70.311 Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg
I70.312 Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg
I70.313 Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs
I70.318 Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
I70.319 Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity
I70.321 Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg
I70.322 Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg
I70.323 Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs
I70.328 Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity
I70.329 Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity
I70.331 Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh
I70.332 Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf
I70.333 Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle
I70.334 Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot
I70.335 Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot
I70.338 Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg
I70.339 Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site
I70.341 Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh
I70.342 Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf
I70.343 Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle
I70.344 Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot
I70.345 Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot

Important Safety Information

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please click here to see additional Important Safety Information on page 17.
Atherosclerosis (cont’d)

- **I70.348** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg
- **I70.349** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site
- **I70.35** Atherosclerosis of unspecified type of bypass graft(s) of other extremity with ulceration
- **I70.361** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg
- **I70.362** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg
- **I70.363** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs
- **I70.368** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity
- **I70.369** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity
- **I70.391** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg
- **I70.392** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg
- **I70.393** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs
- **I70.398** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity
- **I70.399** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity
- **I70.401** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg
- **I70.402** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg
- **I70.403** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs
- **I70.408** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity
- **I70.409** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity
- **I70.411** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, right leg
- **I70.412** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, left leg
- **I70.413** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- **I70.418** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, other extremity
- **I70.419** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- **I70.421** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, right leg
- **I70.422** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, left leg
- **I70.423** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, bilateral legs
- **I70.428** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, other extremity
- **I70.429** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, unspecified extremity
- **I70.431** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of thigh
- **I70.432** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of calf
- **I70.433** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of ankle
- **I70.434** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of heel and midfoot

Important Safety Information

**Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Please **click here** to see additional Important Safety Information on page 17.
Diseases of Arteries, Arterioles, and Capillaries (cont’d)

I70.435 Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of foot
I70.438 Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of lower leg
I70.439 Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of unspecified site
I70.441 Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of thigh
I70.442 Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of calf
I70.443 Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of ankle
I70.444 Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of heel and midfoot
I70.445 Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of foot
I70.448 Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of lower leg
I70.449 Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of unspecified site
I70.45 Atherosclerosis of autologous vein bypass graft(s) of other extremity with ulceration
I70.461 Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, right leg
I70.462 Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, left leg
I70.463 Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, bilateral legs
I70.468 Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, other extremity
I70.469 Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, unspecified extremity
I70.491 Other atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg
I70.492 Other atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg
I70.493 Other atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs
I70.498 Other atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity
I70.499 Other atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity
I70.501 Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg
I70.502 Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg
I70.503 Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs

Important Safety Information

Allergic Reactions: Hypersensitivity reactions (e.g. angioedema, rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please click here to see additional Important Safety Information on page 17.
Atherosclerosis (cont’d)

I70.508 Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity
I70.509 Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity
I70.511 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg
I70.512 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg
I70.513 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs
I70.518 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity
I70.519 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
I70.521 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg
I70.522 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg
I70.523 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs
I70.528 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity
I70.529 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity
I70.531 Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh
I70.532 Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf
I70.533 Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle
I70.534 Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot
I70.535 Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot
I70.538 Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg
I70.539 Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site
I70.541 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh
I70.542 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf
I70.543 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle
I70.544 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot
I70.545 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot
I70.548 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg
I70.549 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site
I70.55 Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration
I70.561 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg
I70.562 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg
I70.563 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs

Important Safety Information

Adverse Reactions in Primary Hyperlipidemia (including HeFH): The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

Please click here to see additional Important Safety Information on page 17.
Important Safety Information
From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

Please click here to see additional Important Safety Information on page 17.
Important Safety Information

Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Please click here to see additional Important Safety Information on page 17.
Diseases of Arteries, Arterioles, and Capillaries (cont’d)

I70.719 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
I70.721 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg
I70.722 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg
I70.723 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs
I70.728 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity
I70.729 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity
I70.731 Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh
I70.732 Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf
I70.733 Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle
I70.734 Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot
I70.735 Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot
I70.738 Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg
I70.739 Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site
I70.741 Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh
I70.742 Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf
I70.743 Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle
I70.744 Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot
I70.745 Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot
I70.748 Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg
I70.749 Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site
I70.75 Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration
I70.761 Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg
I70.762 Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg
I70.763 Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs
I70.768 Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity

Important Safety Information

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Please click here to see additional Important Safety Information on page 17.
### Atherosclerosis (cont’d)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I70.769</td>
<td>Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity</td>
</tr>
<tr>
<td>I70.791</td>
<td>Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg</td>
</tr>
<tr>
<td>I70.792</td>
<td>Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg</td>
</tr>
<tr>
<td>I70.793</td>
<td>Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs</td>
</tr>
<tr>
<td>I70.798</td>
<td>Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity</td>
</tr>
<tr>
<td>I70.799</td>
<td>Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity</td>
</tr>
<tr>
<td>I70.8</td>
<td>Atherosclerosis of other arteries</td>
</tr>
<tr>
<td>I70.90</td>
<td>Unspecified atherosclerosis</td>
</tr>
<tr>
<td>I70.91</td>
<td>Generalized atherosclerosis</td>
</tr>
<tr>
<td>I70.92</td>
<td>Chronic total occlusion of artery of the extremities</td>
</tr>
</tbody>
</table>

### Diseases of arteries, arterioles, and capillaries (other)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I73.9</td>
<td>Peripheral vascular disease, unspecified</td>
</tr>
</tbody>
</table>

### Family History

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z83.42</td>
<td>Family history of familial hypercholesterolemia</td>
</tr>
</tbody>
</table>

### Peripheral vascular angioplasty

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z95.820</td>
<td>Peripheral vascular angioplasty status with implants and grafts</td>
</tr>
<tr>
<td>Z98.62</td>
<td>Peripheral vascular angioplasty status</td>
</tr>
</tbody>
</table>

### Other lipid storage disorders

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E75.5</td>
<td>Other lipid storage disorders*</td>
</tr>
</tbody>
</table>

* Other lipid storage disorders include tendon xanthoma.

---

**Important Safety Information**

**Adverse Reactions in the Cardiovascular Outcomes Trial:** Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

Please click here to see additional Important Safety Information on page 17.
Important Safety Information:

- **Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

- **Allergic Reactions:** Hypersensitivity reactions (e.g. angioedema, rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

- **Adverse Reactions in Primary Hyperlipidemia (including HeFH):** The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

  From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

  Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

- **Adverse Reactions in the Cardiovascular Outcomes Trial:** The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

  Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

- **Adverse Reactions in Homozygous Familial Hypercholesterolemia (HoFH):** The adverse reactions that occurred in at least two patients treated with Repatha® and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis.

- **Immunogenicity:** Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Reference: Centers for Medicare & Medicaid Services. 2018 ICD-10 Codes Table and Index.